Assignee
PRELUDE THERAPEUTICS INC
US·20 granted patents·37 pending applications·24 citations·filing 2018–2025
Top patents by PatentIndex Score
57 records- 0194US11254683B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·3 cites·35 claims
- 0294US11214574B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Jan 4, 2022·3 cites·16 claims
- 0392US11702423B2BRM targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·2 cites·18 claims
- 0492US11673893B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·4 cites·10 claims
- 0591US10570140B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·4 cites·29 claims
- 0690US10711007B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2019·Granted Jul 14, 2020·6 cites·26 claims
- 0787US11939340B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·1 cites·24 claims
- 0885US11208416B2Selective inhibitors of protein arginine methytransterase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Dec 28, 2021·1 cites·37 claims
- 0976US2025367205A1Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1073US2022153747A1Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1172US12459950B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·20 claims
- 1272US2024246993A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1372US2024018158A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1471US12486277B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Granted Dec 2, 2025·0 cites·23 claims
- 1571US2025163074A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1669US11078205B2Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Aug 3, 2021·0 cites·26 claims
- 1767US2023174539A1Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1867US2025114354A1Combination treatment regimens - smarca2 degrader with pd-1 inhibitorsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2023357265A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2067US2025074916A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2167US2025114353A1Combination Treatment Regimens - SMARCA2 Degrader With GemcitabinePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2266US2025059175A1Mutant Pi3k-Alpha Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2366US2024352029A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2464US12414953B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Sep 16, 2025·0 cites·70 claims
- 2564US2025161289A1KAT6 Targeting CompoundsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2664US2023010358A1Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) ProteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2764US2024150340A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2863US12129262B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·29 claims
- 2963US11685744B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Jun 27, 2023·0 cites·54 claims
- 3063US11130769B2Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) proteinPRELUDE THERAPEUTICS INC·Filed 2019·Granted Sep 28, 2021·0 cites·31 claims
- 3162US2024018136A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3261US2025011298A1Crystalline forms of a cdk9 inhibitor and uses thereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3361US2024336612A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3460US11524962B2Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2018·Granted Dec 13, 2022·0 cites·23 claims
- 3560US2025361258A1Processes for making prmt5 inhibitorsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3659US2023257394A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3759US2024165244A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3859US2024190886A1BRM Targeting Compounds and Associated Methods of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3959US2024124422A1Mutant pi3k-alpha inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4058US2022251088A1Processes for Making PRMT5 InhibitorsPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4157US2023144528A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4257US2023365576A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4357US2023416240A1Kat6 targeting compoundsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4456US2025197418A1Polymorphic Compounds And Uses ThereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4555US11622970B2BCL-2 inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Apr 11, 2023·0 cites·20 claims
- 4655US2023212191A1Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) proteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4754US2023357275A1Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) proteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4853US2023265083A1Heterocycle CDK Inhibitors And Their Use ThereofPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4951US12448389B2BRM targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2021·Granted Oct 21, 2025·0 cites·29 claims
- 5049US2025281473A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →